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INTRODUCTION
Aliskiren,(2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-
methylpropyl)-5-amino-4 hydroxy2,7 diisopropyl -8-[4-
methoxy-3-(3-methoxypropoxy)phenyl] octanamide 
hemifumarate)1-2 (Fig.1). The first oral direct renin 
inhibitor approved for clinical use, exhibits a novel and 
advantageous pharmacokinetic and pharmacodynamic 
profile for the long-term treatment of hypertension. 
Aliskiren blocks the renin system at its rate-limiting step 
by directly inhibiting the catalytic activity of renin, thereby 
reducing generation of angiotensin I and angiotensin II.
Figure 1; Chemical structure of Aliskiren
Valsartan (VAL) is chemically, N ‐ (1 ‐ oxopentyl) ‐ N ‐
[(2' ‐ (1H ‐ tetrazol ‐ 5 ‐ yl) (1, 1' ‐ biphenyl) ‐ 4 ‐ yl) 
methyl] ‐ L – valine (Fig. 2), is a potent angiotensin 
receptor blocker.
Literature survey reveals the availability of several 
methods for estimation of both Aliskiren and Valsartan 3
and Valsartan 4includes UV, HPLC as alone or in 
combination with other drugs. No method has been 
reported for the estimation of Aliskiren and Valsartan in 
combined dosage form. Present work emphasizes on the 
quantitative estimation of Aliskiren and Valsartan in their 
combined dosage form (Valturna) by RP-HPLC.
Figure 2: Chemical structure of Valsartan
MATERIALS AND METHODS
Experimental
Chromatographic conditions
The analysis of the drug was carried out on a Waters 
HPLC system equipped with a reverse phase Hiber@ 
Lichrosphere ® C18 column (250mmx4.6mm; 5μm), a 515 
binary pump, a 20 μl injection loop and a 2487 dual 
absorbance detector and running on Waters Empower 
software. The UV spectrum of the drugs was taken using a 
shimadz-1800 UV-Visible spectrophotometer.
Instrumentation
The present work was carried out on Water’s HPLC 
equipped with UV-Visible detectors with pair of 10 mm 
matched quartz cells. Glassware’s used were of ‘A’ grade 
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and were soaked overnight in a mixture of chromic acid 
and sulphuric acid, rinsed thoroughly with double distilled 
water and dried in hot air oven.
Chemicals and Solvents
The Aliskiren and Valsartan Working standards were 
kindly gifted by Dr .reddys Laboratories Hyderabad. And 
Morepen Laboratories Ltd, New Delhi-India. HPLC grade 
water and acetonitrile were purchased from E. Merck 
(India) Ltd., Mumbai. Potassium dihydrogen phosphate 
and orthophosphoric acid of AR Grade were obtained from 
S.D. Fine Chemicals Ltd., Mumbai.
Preparation of phosphate buffer (pH 3.0)
Seven grams of KH2PO4 was weighed into a 1000 ml 
beaker, dissolved and diluted to 1000 ml with HPLC water 
and pH adjusted to 3.0 with orthophosporic acid.
Preparation of mobile phase and diluents
500 ml of the methanol and phosphate buffer 300 ml was 
mixed with 200 ml of acetonitrile. The solution was 
degassed in an ultrasonic water bath for 5 minutes and 
filtered through 0.45μ filter under vacuum.
Procedure
A mixture of methanol and buffer and acetonitrile in the 
ratio of 50:30:20 v/v was found to be the most suitable 
mobile phase for ideal separation of Aliskiren and 
Valsartan. The solvent mixture was filtered through a 
0.45μ membrane filter and sonicated before use. It was 
pumped through the column at a flow rate of 1.0 ml/min. 
The column was maintained at ambient temperature. The 
pump pressure was set at 1700 psi. The column was 
equilibrated by pumping the mobile phase through the 
column for at least 30 min prior to the injection of the drug 
solution. The detection of the drug was monitored at 271 
nm. The run time was set at 10 min. Under these optimized 
chromatographic conditions the retention time obtained for
the drugs Aliskiren and Valsartan were 6.92 min and 7.9 
min. A typical chromatogram showing the separation of 
the drug is given in Fig. 3.
Figure 3: Typical chromatogram for Aliskiren and Valsartan.
Calibration plot
About 100 mg of Aliskiren and 100 mg of valsartan was 
weighed accurately,transferred into a 100 ml volumetric 
flask and dissolved in 25 ml of a 50:30:20 v/v mixture of 
methanol and  Phosphate buffer and acetonitrile. The 
solution was sonicated for 15 min and the volume made 
up to the mark with a further quantity of the diluent to get 
a 1000μg/ml solution. From this, a working standard 
solution of the drugs (20μg/ml for Aliskiren and 20μg/ml 
for Valsartan) was prepared by diluting the above 
solution to 10 ml in a volumetric flask. Further dilutions 
ranging from 10-50μg/ml for Aliskiren and 10-50μg/ml 
for Valsartan) were prepared from the solution in10 ml 
volumetric flasks using the above diluents.20 μl of each 
dilution was injected six times into the column at a flow 
rate of 1.0 ml/min and the corresponding chromatograms 
were obtained. From these chromatograms, the average 
area under the peak of each dilution was computed. The 
calibration graph constructed by plotting concentration of 
the drug against peak area was found to be linear in the 
concentration range of 10-50μg/ml for Aliskiren and 10-
50μg/ml for Valsartan. The relevant data are furnished in 
Table 1&2 and fig.4&5. The regression equations of this 
curves was computed. This regression equation was later 
used to estimate the amount of Aliskiren and valsartan in 
tablets dosage forms.
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Table 1: Calibration data for Aliskiren
Figure 4: Calibration graph for Aliskiren.
Table 2: Calibration data for Valsartan
Validation of the proposed method5-9
The specificity, linearity, precision, accuracy, limit of 
detection, limit of quantification, robustness and system 
suitability parameters were studied systematically to 
validate the proposed HPLC method for the determination 
of Aliskiren and valsartan.
Solution containing 20μg/ml for Aliskiren and 20μg/ml 
for valsartan was subjected to the proposed HPLC 
analysis to check intra-day and interday variation of the 
method and the results are furnished in Table 3&4. The 
accuracy of the HPLC method was assessed by analyzing 
solutions of Aliskiren and valsartan at 50, 100 and 150% 
concentrated levels by the proposed method. The results 
are furnished in Table 5. The system suitability 
parameters are given in Table 6.
Figure 5: Calibration graph for Valsartan
Table 3 .Precision of the proposed HPLC method 
(Aliskiren)
S.NO. Concentration 
of
Aliskiren 
(20µg/ml)
Peak area
Intra-day Inter-day
1. Injection-1 456881 498581
2. Injection-2 478581 498781
3. Injection-3 497861 498681
4. Injection-4 498581 498781
5. Injection-5 497781 498781
6. Average 485937 498721
7. Standard 
Deviation 18307.75 89.44272
8. %RSD 3.767515 0.017934
Table 4 .Precision of the proposed HPLC method (Valsartan)
S.NO. Concentration of
valsartan(20µg/ml)
Peak area
Intra-day Inter-day
1. Injection-1 1289943 1289943
2. Injection-2 1290953 1290953
3. Injection-3 1299913 1299913
4. Injection-4 1298913 1298913
5. Injection-5 1297913 1297913
6. Average 1295527 1295527
7. Standard Deviation 4703.656 4703.656
8. %RSD 0.363069 0.363069
S.No Concentration
(µg/ml)
Peak Area
(n=5)
1. 10 278636
2. 20 498881
3. 30 784446
4. 40 1042985
5. 50 1283891
S.No Concentration
(µg/ml)
Peak Area
(n=5)
1. 10 648739
2. 20 1290913
3. 30 1922395
4. 40 2484620
5. 50 3085316
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Table 5: Accuracy studies
S.No
Concentration
Amount added (mg) Amount found (mg) % Recovery % Mean recovery
ALN VLN ALN VLN ALN VLN
1 50% 5.0 5.03 5.03 5.15 98.40 97.66 98.03
2 100% 10.1 10.04 9.97 10.03 100.59 99.40 99.95
3 150% 15.0 15.02 14.96 15.1 99.86 99.07 99.20
    
Estimation of Aliskiren and valsartan in tablet dosage forms.
Two commercial brands of tablets were chosen for testing 
the suitability of the proposed method to estimate 
Aliskiren and valsartan in tablet formulations. Twenty 
tablets were weighed and powdered. An accurately 
weighed portion of this powder equivalent to 100 mg of 
Aliskiren and and 100 mg of valsartan was transferred into 
a 100 ml volumetric flask and dissolved in 25 ml of a 
50:30:20 v/v mixture of methanol and phosphate buffer 
and acetonitrile. The contents of the flask were sonicated 
for 15 min and a further 25 ml of the diluent was added, 
the flask was shaken continuously for 15 min to ensure 
complete solubility of the drug. The volume was made up 
with the diluent and the solution was filtered through a 
0.45μ membrane filter. This solution was further diluted to 
get the required concentrations. This solution was injected 
into the column six times. The average peak area of the 
drugs was computed from the chromatograms and the 
amount of the drug present in the tablet dosage form was 
calculated by using the regression equation obtained for 
the pure drug. The relevant results are furnished in Table 
7.
Table 6: System suitability parameters
Parameter Result
(Aliskiren)
Result
(Valsartan)
Linearity (µg/ml) 10-50 10-50
Correlation 
coefficient
0.999 0.999
Tailing factor 1.25 1.57
LOD (µg/ml) 1.20 0.25
LOQ(µg/ml) 3.6 0.42
Table 7: Assay Results for Tablets Using the Proposed Method
RESULTS AND DISCUSSION
In the proposed method, the retention time of Aliskiren 
and valsartan was found to be 6.9 min and 7.9 min. 
Quantification was linear in the concentration range of 10-
50μg/ml for Aliskiren and 10-50μg/ml for valsartan. The 
regression equation of the linearity plot of concentration of 
Aliskiren over its peak area was found to be 
Y=25546.14+11383.6X (r2=0.999) for Aliskiren and 
Y=60668.61+66338.37X (r2=0.999) for valsartan, where X 
is the concentration of Aliskiren and valsartan (μg/ml) and 
Y is the corresponding peak area. The number of 
theoretical plates calculated was 6083 for Aliskiren and 
3510 for valsartan, which indicates efficient performance 
of the column. The limit of detection and limit of 
quantification for Aliskiren were found to be 0.02 μg/ml 
and 0.08 μg/ml and for valsartan were found to be 0.01 
μg/ml and 0.03 μg/ml respectively, which indicate the 
sensitivity of the method. The use of methanol and 
phosphate buffer and acetonitrile in the ratio of 50:30: 20 
v/v resulted in peak with good shape and resolution.
The high percentage of recovery indicates that the 
proposed method is highly accurate. No interfering peaks 
were found in the chromatogram of the formulation within 
the run time indicating that excipients used in tablet 
formulations did not interfere with the estimation of the 
drug by the proposed HPLC method
CONCLUSION
The developed UV spectroscopic method was validated 
and the statistical validation was performed with the 
simplicity and ease of operation ensures that the validated 
method can successfully used for routine analysis of 
Aliskiren hemifumarate and Valsartan in bulk and tablet 
dosage formulation.
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Label claim (Valturna-150/160mg) Amount found (mg) % Amount found
ALN VLN ALN VLN ALN VLN
150 160 150.03 159.75 99.98 99.84
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